Lymphomas

Common Treatments

 

Commonly Used Medications for Hodgkin Lymphoma

Chemotherapy
bleomycin (Blenoxane)
brentuximab vedotin (Adcetris)
chlorambucil (Leukeran)
cyclophosphamide
dacarbazine (DTIC-Dome)
doxorubicin hydrochloride (Adriamycin)
mechlorethamine (Mustargen)
nivolumab (Opdivo)
pembrolizumab (Keytruda)
prednisone
procarbazine (Matulane)
vinblastine (Velban)
vincristine (Oncovin)
Some Possible Combination Therapies
AAVD: doxorubicin (Adriamycin), brentuximab vedotin (Adcetris), vinblastine (Velban) and dacarbazine (DTIC-Dome)
ABVD: doxorubicin (Adriamycin), bleomycin (Blenoxane), vinblastine (Velban) and dacarbazine (DTIC-Dome)
ABVD + R: doxorubicin (Adriamycin), bleomycin (Blenoxane), vinblastine (Velban), dacarbazine (DTIC-Dome) and rituximab (Rituxan)
BEACOPP: bleomycin (Blenoxane), etoposide (Etopophos), doxorubicin (Adriamycin), cyclophosphamide, vincristine (Oncovin), procarbazine (Matulane) and prednisone
ChlVPP: chlorambucil (Leukeran), vinblastine (Velban), procarbazine (Matulane) and prednisone
DHAP: dexamethasone, high-dose cytarabine and cisplatin
ESHAP: etoposide (Etopophos), methylprednisolone, high-dose cytarabine and cisplatin
GDP: gemcitabine (Gemzar), dexamethasone and cisplatin
Gem-Ox: gemcitabine (Gemzar) and oxaliplatin (Eloxatin)
GVD: gemcitabine (Gemzar), vinorelbine (Navelbine) and doxorubicin
ICE: ifosfamide, carboplatin and etoposide (Etopophos)
Stanford V: doxorubicin (Adriamycin), mechlorethamine (Mustargen), vincristine (Oncovin), bleomycin (Blenoxane), etoposide (Etopophos) and prednisone

As of 12/18/20

 

Commonly Used Medications for Non-Hodgkin Lymphoma

Chemotherapy
acalabrutinib (Calquence)
axicabtagene ciloleucel (Yescarta)
bendamustine (Bendeka)
bleomycin (Blenoxane)
bortezomib (Velcade)
brentuximab vedotin (Adcetris)
brexucabtagene autoleucel (Tecartus)
carboplatin
chlorambucil (Leukeran)
cisplatin
copanlisib (Aliqopa)
cyclophosphamide
dexamethasone
doxorubicin hydrochloride (Adriamycin)
duvelisib (Copiktra)
ibritumomab (Zevalin)
ibrutinib (Imbruvica)
idelalisib (Zydelig)
lenalidomide (Revlimid)
mechlorethamine (Mustargen)
methotrexate
methylprednisolone
mogamulizumab-kpkc (Poteligeo)
obinutuzumab (Gazyva)
pembrolizumab (Keytruda)
prednisone
procarbazine (Matulane)
rituximab (Rituxan)
rituximab and hyaluronidase human (Rituxan Hycela)
rituximab-abbs (Truxima)
rituximab-arrx (Riabni)
rituximab-pvvr (Ruxience)
selinexor (Xpovio)
tazemetostat (Tazverik)
tisagenlecleucel (Kymriah)
venetoclax (Venclexta)
vinblastine (Velban)
vincristine (Oncovin)
zanubrutinib (Brukinsa)
Some Possible Combinations
BR: bendamustine (Bendeka) and rituximab (Rituxan)
CHOP: cyclophosphamide, doxorubicin (Adriamycin), vincristine (Oncovin) and prednisone
CODOX-M/IVAC: cyclophosphamide, vincristine (Oncovin), doxorubicin (Adriamycin) and intrathecal methotrexate, and cytarabine followed by high-dose systemic methotrexate and rituximab (Rituxan)
CVP: cyclophosphamide, vincristine (Oncovin) and prednisone
EPOCH-R: etoposide (Etopophos), prednisone, vincristine (Oncovin), cyclophosphamide and doxorubicin (Adriamycin) and rituximab (Rituxan)
Hyper-CVAD: cyclophosphamide, vincristine (Oncovin), doxorubicin (Adriamycin) and dexamethasone, alternating with high-dose methotrexate plus cytarabine and rituximab (Rituxan)
lenalidomide (Revlimid) with rituximab product
P+BR: polatuzumab (Polivy), bendamustine (Bendeka) and rituximab (Rituxan)
polatuzumab vedotin-piiq (Polivy) with bendamustine (Bendeka) and a rituximab product
R-CHOP: rituximab (Rituxan), cyclophosphamide, doxorubicin (Adriamycin), vincristine (Oncovin) and prednisone
R-CVP: rituximab (Rituxan), cyclophosphamide, vincristine (Oncovin) and prednisone
rituximab and hyaluronidase human (Rituxan Hycela) with first-line chemotherapy
tafasitamab-cxix (Monjuvi) with lenalidomide (Revlimid)

As of 12/18/20

 

Previous Next